Observational studies of drug safety--aprotinin and the absence of transparency.
Hiatt
William R
WR
University of Colorado School of Medicine and Colorado Prevention Center, Denver, USA.
D026683:Advisory Committees; D000933:Antifibrinolytic Agents / Q000009:adverse effects*; D007611:Aprotinin / Q000009:adverse effects*; D006348:Cardiac Surgical Procedures; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D019370:Observation; D011358:Product Surveillance, Postmarketing; D051437:Renal Insufficiency / Q000139:chemically induced*; D012107:Research Design; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
D000933:Antifibrinolytic Agents; D007611:Aprotinin